Avalyn Pharma Inc. filed a Form S-1 registration statement for an initial public offering on 2026-04-08. It has amended it 2 times. It filed its final prospectus on 2026-04-30, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “AVLN.”From the 424B4 filed 2026-04-30
Shares offered
This is the initial public offering of shares of common stock of Avalyn Pharma Inc. We are offering 16,666,667 shares of our common stock.From the 424B4 filed 2026-04-30
Offering price
The initial public offering price per share is $18.00.From the 424B4 filed 2026-04-30
Use of proceeds
We currently intend to use the net proceeds we receive from this offering, together with our existing cash, cash equivalents, and marketable securities to fund the continued development of AP01 and AP02, our two clinical stage programs, and AP03, our preclinical stage program, as well as to fund research and development activities for additional programs, and the remainder for working capital and general corporate purposes.From the 424B4 filed 2026-04-30
Net loss or income
Our net losses were $85.2 million and $49.7 million for the years ended December 31, 2025 and 2024, respectively.From the S-1/A filed 2026-04-29
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-04-08 | Registration statement filed | S-1 |
| 2026-04-23 | Registration statement amended | S-1/A |
| 2026-04-29 | Registration statement amended | S-1/A |
| 2026-04-30 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Avalyn Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.